Here we identified those empirical studies and involved them in a systematic review of clinical studies and a meta-analysis, aiming to evaluate the effects of including Pentoxifylline (PTX) in the treatment of acute COVID-19, covering its influence on several clinical outcomes and inflammatory markers, including length of hospital stay, mortality rate, ICU admission, adverse events, CRP, IL-6, and LDH, and could be considered the first one assessing empirical data on the topic. This evidence concerns the gene IL6 and COVID-19.